Question

Future Plus Ltd is a biotechnology company that was listed on the Australian Securities Exchange on 1 July 2018 following a very successful initial public offering of shares. The company is involved in research and the commercialisation of recent medical breakthroughs.
Its managing director is Professor Tony Theodore, a world-renowned figure in medical and biotechnology research. The board of directors of Future Plus Ltd is about to discuss the preparation of financial statements for the company’s first year of operations (year ended 30 June 2019).
The managing director has put forward the following views about the Company’s financial statements:
• The entire company and its staff, whether security officers, secretaries or researchers, is focused on the company’s mission of commercialising research. Hence, the entire $30 million of non-capital spending during the year has contributed to the development of intellectual capital in the company.

As the market value of the company ($250 million) far exceeds the company’s book value, it is clear that all expenditures in the current year have added value to the company and should be capitalised as intellectual capital. The managing director expects further market value increases in the future and thus sees no reason for any amortisation of these capitalised amounts.

• The company is currently working on three research projects, and expenditures directly related to these projects total $18 million. Despite some setbacks on one project, the managing director is ‘supremely confident’ that all projects will be brought to a successful conclusion. As yet, no projects have reached the stage of starting commercial production.

Required:
Write a brief report to the board of directors evaluating the managing director’s views in light of relevant accounting standards.

Answer 1

To,

The BOD of the company

The relevent treatment of expenses by Managing director's Doesnot go with the Ifrs

As company is dealing in research and is listed on stock exchange means company comes in operation as the main object of business of company is research as

Under IFRS, the research expenditures are treated as expenses while the development expenditures are capitalized as an asset.

In That case managing director thinks that the expenditure of $30 million spends has increase company networth so it so should be treated as capitalised value

As per Ifrs 8 Operating Segments equires an entity whose debt or equity securities are publicly traded to disclose information to enable users of its financial statements to evaluate the nature and financial effects of the different business activities in which it engages and the different economic environments in which it operates.
It specifies how an entity should report information about its operating segments in annual financial statements and in interim financial reports. It also sets out requirements for related disclosures about products and services, geographical areas and major customers.

and it also mention that the amounts reported for each operating
segment shall be measured on the same basis as that used by the
chief operating decision maker for the purposes of allocating resources
to the segments and assessing its performance.

But as per the company information provided the $ 30 million spend has increase the compnay net worth so it can be capitalised as per manager direction and as per ifrs 8 but the expenses $18 million cannot be capitalised as the project company working has not generated any goodwill or net woth the company and decisions cannot be made on mere assuptions in fianancial reporting so $ 18 million will be treated as expenses as company is in field of reserach.